0001410578-22-002405.txt : 20220812 0001410578-22-002405.hdr.sgml : 20220812 20220812161351 ACCESSION NUMBER: 0001410578-22-002405 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220812 DATE AS OF CHANGE: 20220812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IBERE PHARMACEUTICALS CENTRAL INDEX KEY: 0001835205 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 981564986 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40119 FILM NUMBER: 221160226 BUSINESS ADDRESS: STREET 1: 2005 MARKET STREET, SUITE 2030 CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 267-765-3222 MAIL ADDRESS: STREET 1: 2005 MARKET STREET, SUITE 2030 CITY: PHILADELPHIA STATE: PA ZIP: 19103 10-Q 1 tmb-20220630x10q.htm 10-Q
138000001380000013800000914917134500003450000345000032983430001835205--12-312022Q2falsefalse00000034500003450000138000003450000138000003450000138000001380000034500003450000138000003450000914917132983430.090.010.290.250.080.010.290.840.090.080.010.010.290.290.250.840.5http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants0001835205us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberiber:PrivatePlacementWarrantsMember2022-06-300001835205us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberiber:PublicWarrantsMember2022-06-300001835205us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberiber:PrivatePlacementWarrantsMember2021-12-310001835205us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberiber:PublicWarrantsMember2021-12-310001835205iber:PublicWarrantsMember2021-12-310001835205iber:PrivatePlacementWarrantsMember2021-12-310001835205iber:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2022-06-300001835205iber:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2022-03-310001835205iber:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2021-12-310001835205iber:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2021-06-300001835205iber:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2021-03-310001835205iber:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2020-12-310001835205iber:CommonClassaSubjectToRedemptionMember2022-06-300001835205iber:CommonClassaSubjectToRedemptionMember2021-12-310001835205iber:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2022-04-012022-06-300001835205iber:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2022-01-012022-03-310001835205iber:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2021-04-012021-06-300001835205us-gaap:RetainedEarningsMember2022-06-300001835205us-gaap:RetainedEarningsMember2022-03-3100018352052022-03-310001835205us-gaap:RetainedEarningsMember2021-12-310001835205us-gaap:RetainedEarningsMember2021-06-300001835205us-gaap:RetainedEarningsMember2021-03-3100018352052021-03-310001835205us-gaap:RetainedEarningsMember2020-12-310001835205us-gaap:AdditionalPaidInCapitalMember2020-12-310001835205us-gaap:OverAllotmentOptionMember2021-03-020001835205us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-06-300001835205us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-03-310001835205us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001835205us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-06-300001835205us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-03-310001835205us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001835205iber:SimplePromissoryNoteWithRelatedPartyMember2022-01-012022-06-300001835205iber:PromissoryNoteWithRelatedPartyMember2021-04-160001835205iber:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-03-022021-03-0200018352052021-02-252021-02-250001835205iber:PromissoryNoteWithRelatedPartyMember2021-12-310001835205us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2021-12-310001835205us-gaap:FairValueMeasurementsRecurringMemberiber:PublicWarrantsMember2021-12-310001835205us-gaap:FairValueMeasurementsRecurringMemberiber:PrivatePlacementWarrantsMember2021-12-310001835205us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2020-12-310001835205us-gaap:FairValueMeasurementsRecurringMemberiber:PublicWarrantsMember2020-12-310001835205us-gaap:FairValueMeasurementsRecurringMemberiber:PrivatePlacementWarrantsMember2020-12-310001835205iber:PrivatePlacementWarrantsMember2022-01-012022-06-300001835205us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2021-01-012021-12-310001835205us-gaap:FairValueMeasurementsRecurringMemberiber:PublicWarrantsMember2021-01-012021-12-310001835205us-gaap:FairValueMeasurementsRecurringMemberiber:PrivatePlacementWarrantsMember2021-01-012021-12-310001835205us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2021-01-012021-12-310001835205us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberiber:PrivatePlacementWarrantsMember2021-01-012021-12-310001835205us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2021-01-012021-12-310001835205us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberiber:PublicWarrantsMember2021-01-012021-12-310001835205us-gaap:FairValueInputsLevel2Member2021-01-012021-12-310001835205us-gaap:CommonClassBMember2022-04-012022-06-300001835205us-gaap:CommonClassAMember2022-04-012022-06-300001835205us-gaap:CommonClassBMember2022-01-012022-06-300001835205us-gaap:CommonClassBMember2021-04-012021-06-300001835205us-gaap:CommonClassAMember2021-04-012021-06-300001835205us-gaap:CommonClassBMember2021-01-012021-06-300001835205us-gaap:CommonClassAMember2021-01-012021-06-300001835205us-gaap:MeasurementInputSharePriceMember2021-03-020001835205us-gaap:MeasurementInputRiskFreeInterestRateMember2021-03-020001835205us-gaap:MeasurementInputPriceVolatilityMember2021-03-020001835205us-gaap:MeasurementInputExpectedTermMember2021-03-020001835205us-gaap:MeasurementInputExercisePriceMember2021-03-020001835205iber:SimplePromissoryNoteWithRelatedPartyMember2022-06-300001835205iber:PromissoryNoteWithRelatedPartyMember2022-05-050001835205iber:PromissoryNoteWithRelatedPartyMember2020-11-150001835205us-gaap:CommonClassBMember2021-02-150001835205us-gaap:CommonClassBMember2021-12-310001835205us-gaap:CommonClassAMember2021-12-310001835205iber:SponsorMemberus-gaap:CommonClassBMember2021-02-252021-02-250001835205iber:PrivatePlacementWarrantsMemberus-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2021-03-020001835205iber:PublicWarrantsMemberus-gaap:IPOMember2021-03-020001835205iber:PublicWarrantsMember2021-03-020001835205iber:PrivatePlacementWarrantsMember2021-03-0200018352052021-06-3000018352052020-12-310001835205us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001835205us-gaap:USTreasurySecuritiesMember2022-06-300001835205us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001835205us-gaap:USTreasurySecuritiesMember2021-12-310001835205iber:FounderSharesMemberiber:SponsorMember2022-01-012022-06-300001835205iber:PrivatePlacementWarrantsMember2021-02-250001835205us-gaap:RetainedEarningsMember2022-01-012022-06-300001835205us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001835205us-gaap:RetainedEarningsMember2021-01-012021-12-310001835205us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-3100018352052021-01-012021-12-310001835205us-gaap:OverAllotmentOptionMember2021-03-022021-03-020001835205us-gaap:IPOMember2021-03-022021-03-020001835205iber:FounderSharesMemberiber:SponsorMemberus-gaap:CommonClassBMember2022-01-012022-06-300001835205iber:WarrantsMember2022-01-012022-06-300001835205us-gaap:IPOMember2022-01-012022-06-300001835205iber:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2021-01-012021-03-310001835205iber:FounderSharesMemberus-gaap:OverAllotmentOptionMember2021-03-022021-03-020001835205iber:SponsorMemberus-gaap:CommonClassBMember2020-11-152020-11-150001835205iber:SponsorMemberus-gaap:CommonClassBMember2022-01-012022-06-300001835205iber:FounderSharesMemberiber:SponsorMember2021-01-110001835205iber:NonRedeemableSharesMember2022-04-012022-06-300001835205iber:ClassPublicSharesMember2022-01-012022-06-3000018352052021-03-022021-03-020001835205iber:PublicWarrantsMemberus-gaap:IPOMember2021-03-022021-03-020001835205iber:FounderSharesMemberiber:SponsorMember2021-01-112021-01-110001835205us-gaap:WarrantMember2022-01-012022-06-3000018352052021-01-012021-06-300001835205us-gaap:IPOMember2021-03-0200018352052021-03-0200018352052020-10-222020-10-220001835205us-gaap:RetainedEarningsMember2022-04-012022-06-3000018352052022-04-012022-06-300001835205us-gaap:RetainedEarningsMember2022-01-012022-03-3100018352052022-01-012022-03-310001835205us-gaap:RetainedEarningsMember2021-04-012021-06-3000018352052021-04-012021-06-300001835205us-gaap:RetainedEarningsMember2021-01-012021-03-310001835205us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100018352052021-01-012021-03-310001835205us-gaap:CommonClassBMember2022-06-300001835205us-gaap:CommonClassAMember2022-06-300001835205iber:PrivatePlacementWarrantsMember2022-06-300001835205iber:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-03-0200018352052022-06-3000018352052021-12-310001835205us-gaap:CommonClassAMember2022-01-012022-06-300001835205iber:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember2022-01-012022-06-300001835205iber:UnitsEachConsistingOfOneShareOfClassCommonStockAndOneHalfOfOneWarrantMember2022-01-012022-06-300001835205us-gaap:CommonClassBMember2022-08-120001835205us-gaap:CommonClassAMember2022-08-1200018352052022-01-012022-06-30xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesiber:Diber:Voteiber:director

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended June 30, 2022

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to

Commission file number: 001-40119

Ibere Pharmaceuticals

(Exact Name of Registrant as Specified in Its Charter)

Cayman Islands

    

98-1564986

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.) 

2005 Market Street, Suite 2030

Philadelphia, PA 19103

(Address of principal executive offices)

(267) 765-3222

(Issuer’s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant

 

IBERU

New York Stock Exchange

Class A ordinary share, $0.0001 par value

 

IBER

 

New York Stock Exchange

Warrants, each whole warrant exercisable for one Class A ordinary share for $11.50 per share

 

IBERW

 

New York Stock Exchange

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes   No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

As of August 12, 2022, there were 13,800,000 Class A ordinary shares, par value $0.0001 per share, and 3,450,000 Class B ordinary shares, par value $0.0001 per share, issued and outstanding.

IBERE PHARMACEUTICALS

FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2022

TABLE OF CONTENTS

Page

Part I. Financial Information

Item 1.

Financial Statements

Condensed Balance Sheets as of June 30, 2022 (Unaudited) and December 31, 2021

1

Condensed Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 (Unaudited)

2

Condensed Statements of Changes in Shareholders’ (Deficit) Equity for the Three and Six Months Ended June 30, 2022 and 2021 (Unaudited)

3

Condensed Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 (Unaudited)

4

Notes to Condensed Financial Statements (Unaudited)

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

20

Item 3.

Quantitative and Qualitative Disclosures Regarding Market Risk

22

Item 4.

Controls and Procedures

22

Part II. Other Information

23

Item 1.

Legal Proceedings

23

Item 1A.

Risk Factors

23

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

24

Item 3.

Defaults Upon Senior Securities

24

Item 4.

Mine Safety Disclosures

24

Item 5.

Other Information

24

Item 6.

Exhibits

25

Part III. Signatures

26

PART I - FINANCIAL INFORMATION

Item 1. Interim Financial Statements.

IBERE PHARMACEUTICALS

CONDENSED BALANCE SHEETS

(UNAUDITED)

    

June 30, 2022

    

December 31, 2021

ASSETS

Current assets

Cash

$

93,041

$

458,388

Prepaid expenses

 

182,770

 

235,000

Total Current Assets

275,811

693,388

 

 

Marketable securities held in trust account

138,108,723

138,016,940

TOTAL ASSETS

$

138,384,534

$

138,710,328

LIABILITIES, REDEEMABLE ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT

 

  

 

  

Current liabilities

 

  

Accrued expenses

$

239,142

$

372,444

Promissory note - related party

158,866

Total Current Liabilities

398,008

372,444

Deferred underwriting fee payable

 

4,830,000

 

4,830,000

Warrant liability

 

938,800

 

6,336,900

TOTAL LIABILITIES

 

6,166,808

 

11,539,344

 

  

 

  

Commitments and Contingencies

 

  

 

  

Class A ordinary shares subject to possible redemption 13,800,000 shares at June 30, 2022 and December 31, 2021, at redemption value

138,108,723

138,016,940

 

  

 

  

Shareholders’ Deficit

 

  

 

  

Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding

 

 

Class A ordinary shares, $0.0001 par value; 300,000,000 shares authorized; no shares issued and outstanding (excluding 13,800,000 shares subject to possible redemption) at June 30, 2022 and December 31, 2021

 

 

Class B ordinary shares, $0.0001 par value; 30,000,000 shares authorized; 3,450,000 shares issued and outstanding, at June 30, 2022 and December 31, 2021

 

345

 

345

Additional paid-in capital

 

 

Accumulated deficit

 

(5,891,342)

 

(10,846,301)

Total Shareholders’ Deficit

 

(5,890,997)

 

(10,845,956)

TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT

$

138,384,534

$

138,710,328

The accompanying notes are an integral part of the unaudited condensed financial statements.

1

IBERE PHARMACEUTICALS

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2022

    

2021

    

2022

    

2021

Operating and formation costs

$

140,527

$

233,757

$

443,141

$

328,235

Loss from operations

(140,527)

(233,757)

(443,141)

(328,235)

Other income (expense):

Interest earned on marketable securities held in trust account

88,380

6,129

91,783

8,715

Interest income - bank

176

Transaction costs allocable to warrant liabilities

(364,321)

Unrealized loss on marketable securities held in trust account

(1,989)

Change in fair value of warrants

1,525,550

117,350

5,398,100

165,700

Total other income (expense), net

1,613,930

121,490

5,489,883

(189,730)

Net income (loss)

$

1,473,403

$

(112,267)

$

5,046,742

$

(517,965)

 

 

Basic and diluted weighted average shares outstanding, Class A ordinary shares

 

13,800,000

13,800,000

13,800,000

9,149,171

Basic and diluted net income (loss) per share, Class A ordinary shares

$

0.09

$

(0.01)

$

0.29

$

0.25

 

Basic and diluted weighted average shares outstanding, Class B ordinary shares

 

3,450,000

3,450,000

3,450,000

 

3,298,343

Basic and diluted net income (loss) per share, Class B ordinary shares

$

0.08

$

(0.01)

$

0.29

$

(0.84)

The accompanying notes are an integral part of the unaudited condensed financial statements.

2

IBERE PHARMACEUTICALS

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ (DEFICIT) EQUITY

(UNAUDITED)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022

Class A

Ordinary Shares

  

  

Class B

Additional

Total

Subject to Redemption

Ordinary Shares

Paid-in

Accumulated

Shareholders’

    

Shares

    

Amount

  

  

Shares

    

Amount

    

Capital

    

Deficit

    

Deficit

Balance — January 1, 2022

13,800,000

$

138,016,940

3,450,000

$

345

$

$

(10,846,301)

$

(10,845,956)

Accretion of Class A Ordinary shares subject to possible redemption

3,403

(3,403)

(3,403)

Net income

3,573,339

3,573,339

Balance - March 31, 2022

13,800,000

$

138,020,343

3,450,000

$

345

$

$

(7,276,365)

$

(7,276,020)

Accretion of Class A Ordinary shares subject to possible redemption

88,380

(88,380)

(88,380)

Net income

1,473,403

1,473,403

Balance - June 30, 2022

13,800,000

$

138,108,723

3,450,000

$

345

$

$

(5,891,342)

$

(5,890,997)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021

Class A

Ordinary Shares

Class B

Additional

Total

Subject to Redemption

Ordinary Shares

Paid-in

Accumulated

Shareholders’

    

Shares

    

Amount

  

  

Shares

    

Amount

    

Capital

    

Deficit

    

Equity (Deficit)

Balance — January 1, 2021

$

3,450,000

$

345

$

24,655

$

(5,759)

$

19,241

Sale of Unit Purchase Option

13,800,000

124,622,996

Proceeds in excess of fair value of Private Placement Warrants

967,000

967,000

Accretion of Class A Ordinary shares subject to possible redemption

13,381,579

(991,655)

(12,389,924)

(13,381,579)

Net loss

 

 

 

 

(405,698)

 

(405,698)

Balance — March 31, 2021

 

13,800,000

$

138,004,575

3,450,000

$

345

$

$

(12,801,381)

$

(12,801,036)

Accretion of Class A Ordinary shares subject to possible redemption

4,140

(4,140)

(4,140)

Net loss

(112,267)

(112,267)

Balance - June 30, 2021

13,800,000

$

138,008,715

3,450,000

$

345

$

$

(12,917,788)

$

(12,917,443)

The accompanying notes are an integral part of the unaudited condensed financial statements.

3

IBERE PHARMACEUTICALS

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

For the Six

For the Six

Months Ended

Months Ended

June 30, 

June 30, 

    

2022

    

2021

Cash Flows from Operating Activities:

    

  

Net income (loss)

$

5,046,742

$

(517,965)

Adjustments to reconcile net income (loss) to net cash used in operating activities:

 

 

Interest earned on marketable securities held in trust account

(91,783)

(8,715)

Change in fair value of warrant liability

(5,398,100)

(165,700)

Transaction costs allocable to warrant liabilities

364,321

Unrealized loss on marketable securities held in trust account

Changes in operating assets and liabilities:

 

  

 

  

Prepaid expenses

52,230

(350,185)

Accrued expenses

 

(133,302)

 

55,011

Net cash used in operating activities

(524,213)

(623,233)

Cash Flows from Investing Activities:

Investment of cash and marketable securities in trust account

(138,000,000)

Net cash used in investing activities

(138,000,000)

 

  

 

  

Cash Flows from Financing Activities:

 

  

 

  

Proceeds from sale of Units, net of underwriting discounts paid

135,240,000

Proceeds from sale of Private Placement Warrants

4,835,000

Proceeds from promissory note — related party

 

159,666

 

31,159

Repayment of promissory note — related party

 

(800)

 

(200,159)

Payment of offering costs

 

 

(602,325)

Net cash provided by financing activities

158,866

139,303,675

 

  

 

Net Change in Cash

(365,347)

680,442

Cash – Beginning of period

 

458,388

 

175,366

Cash – End of period

$

93,041

$

855,808

 

 

Non-Cash investing and financing activities:

 

 

Offering costs included in accrued offering costs

$

$

154,512

Deferred underwriting fee payable

$

$

4,830,000

The accompanying notes are an integral part of the unaudited condensed financial statements.

4

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(UNaudited)

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Ibere Pharmaceuticals (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on October 22, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”).

The Company is not limited to a particular industry or geographic region for purposes of completing a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

As of June 30, 2022, the Company had not commenced any operations. All activity for the period from October 22, 2020 (inception) through June 30, 2022 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.

The registration statement for the Company’s Initial Public Offering became effective on February 25, 2021. On March 2, 2021, the Company consummated the Initial Public Offering of 13,800,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”), which includes the full exercise by the underwriter of its over-allotment option in the amount of 1,800,000 Units, at $10.00 per Unit, generating gross proceeds of $138,000,000 which is described in Note 3.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 4,835,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to PIPV Capital LLC (the “Sponsor”), generating gross proceeds of $4,835,000, which is described in Note 4.

Transaction costs amounted to $8,359,325, consisting of $2,760,000 of underwriting fees, $4,830,000 of deferred underwriting fees and $769,325 of other offering costs.

Following the closing of the Initial Public Offering on March 2, 2021, an amount of $138,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”), and was invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds in the Trust Account, as described below.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete a Business Combination with one or more target businesses that together have an aggregate fair market value of at least 80% of the value of the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination.

5

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

The Company will provide its holders of the outstanding Public Shares (the “public shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.

The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon such consummation of a Business Combination and, if the Company seeks shareholder approval, in connection with a Business Combination, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who vote at a general meeting of the Company. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or do not vote at all.

Notwithstanding the above, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company.

The Sponsor has agreed (a) to waive its redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, and (b) not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the Company’s initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination or (ii) with respect to any other provision relating to shareholders’ rights or pre-initial business combination activity, unless the Company provides the public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.

The Company has until March 2, 2023 to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than 10 business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, dissolve and liquidate, subject in the case of clauses (ii) and (iii) to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.

6

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

The Sponsor has agreed to waive its liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting discount (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (1) $10.00 per Public Share and (2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes payable; provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

Going Concern and Liquidity

As of June 30, 2022, the Company had $93,041 in its operating bank account, $138,108,723 in securities held in the Trust Account to be used for a Business Combination or to repurchase or redeem its Public Shares in connection therewith and working capital deficit of $122,197. As of June 30, 2022, $108,723 of the amount on deposit in the Trust Account represented interest income, which is available for the Company to pay its tax obligations (less up to $100,000 of interest to pay dissolution expenses).

As of June 30, 2022 the Company’s liquidity needs have been satisfied through receipt of a $25,000 capital contribution from the Sponsor in exchange for the issuance of the Founder Shares to the Sponsor, remaining proceeds from the Initial Public Offering and sale of Private Placement Warrants and notes payable to the Sponsor. The Company expects to continue to incur significant costs in pursuit of its financing and acquisitions plans. In the event the Company does not complete a Business Combination by the date for mandatory liquidation of March 2, 2023, the Company is required to redeem the public shares sold in the Initial Public Offering. Additionally, if the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.

As a result of the above, in connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification Subtopic 205-40, “Presentation of Financial Statements – Going Concern,” management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company’s ability to continue as a going concern through approximately one year from the date these financial statements were issued. These unaudited condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

7

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company Working Capital Loans (Note 5). Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into warrants at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. As of June 30, 2022 and December 31, 2021, the Company has no borrowings under the Working Capital Loans.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial statement, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the period ended December 31, 2021, as filed with the SEC on March 31, 2022. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future periods.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

8

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to credit risk consist principally of cash and marketable securities held in the Trust Account. Cash is maintained in accounts with financial institutions, which, at times may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on its cash accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. The Company’s marketable securities held in the Trust Account consists entirely of U.S. government securities with an original maturity of 180 days or less.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of 180 days or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2022 and December 31, 2021.

Marketable Securities Held in Trust Account

The Company’s portfolio of marketable securities held in the Trust Account are comprised solely of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 180 days or less, classified as trading securities. Trading securities are presented on the unaudited condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities and interest earnings is included in interest earnings on marketable securities held in Trust Account, in the accompanying unaudited condensed statements of operations. The fair value for trading securities is determined using quoted market prices in active markets.

Warrant Liability

The Company accounts for warrants for the Company’s ordinary shares as liabilities at fair value on the unaudited condensed balance sheets because the warrants do not meet the criteria for classification within equity. The warrants are subject to remeasurement at each balance sheet date and any change in fair value is recognized in the unaudited condensed statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants.

9

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

Fair Value Measurements

Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, defines fair value and requires disclosures about fair value measurements. Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

As of June 30, 2022 and December 31, 2021, the recorded values of cash, prepaid expenses, accrued expenses and accounts payable approximate the fair values due to the short-term nature of the instruments. The Company’s marketable securities held in the Trust Account are comprised of U.S. government securities with an original maturity of 180 days or less. The fair value for trading securities is determined using quoted market prices in active markets.

Offering Costs Associated with the Initial Public Offering

Offering costs incurred in connection with preparation of the Initial Public Offering, of approximately $8.4 million, consisted principally of underwriter discounts of $7.6 million (including $4.8 million of which payment is deferred) and approximately $769,000 of professional, printing, filing, regulatory and other costs. These expenses, together with the underwriting discounts and commissions, were allocated to the Class A ordinary shares and the warrants. Amounts allocated to the Class A ordinary shares of $7,995,004 were recognized as a reduction to the Class A ordinary shares carrying value and the amounts allocated to the public warrants of $364,321 were expensed immediately.

Ordinary Shares Subject to Possible Redemption

The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC 480, Distinguishing Liabilities from Equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at June 30, 2022 and December 31, 2021, 13,800,000 ordinary shares subject to possible redemption are presented as temporary equity outside of the shareholders’ equity section of the Company’s unaudited condensed balance sheets.

10

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

The Class A ordinary shares subject to possible redemption are subject to the subsequent measurement guidance in ASC 480-10-S99. Under such guidance, the Company must subsequently measure the shares to their redemption amount because, as a result of the allocation of net proceeds to the Public Warrants, the initial carrying amount of the ordinary shares is less than $10.00 per share. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the subsequent measurement of the initial book value to redemption amount. Subsequent measurement to the carrying value of redeemable Class A ordinary shares is due to interest income and unrealized gains or losses on the marketable securities held in the Trust Account. Such changes are reflected in additional paid-in capital, or in the absence of additional paid-in capital, in accumulated deficit. For the six months ended ended June 30, 2022 and the year ended December 31, 2021, the Company recorded an accretion of $91,783 and $13,393,944, of which $0 and $991,655 was recorded in additional paid-in capital and $91,783 and $12,402,289 was recorded in accumulated deficit, respectively.

Net Income (Loss) Per Ordinary Share

The unaudited condensed statements of operations include a presentation of income (loss) per Class A redeemable public share and income (loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income (loss) attributable to both the Class A redeemable shares and non-redeemable shares, the Company first considered the total income (loss) allocable to both sets of shares. This is calculated using the total net income (loss) less any dividends paid. For purposes of calculating net income (loss) per share, the accretion to redemption value of the Class A ordinary shares subject to possible redemption was considered to be dividends paid to the public shareholders. Subsequent to calculating the total income (loss) allocable to both sets of shares, the company split the amount to be allocated using a ratio of 80% for the Class A public shares and 20% for the non-redeemable shares for the three and six months ended June 30, 2022, reflective of the respective participation rights.

The earnings per share presented in the unaudited condensed statements of operations is based on the following:

For the three

For the three

months ended

months ended

    

June 30, 2022

    

June 30, 2021

Net income (loss)

$

1,473,403

$

(112,267)

Less: Accretion of temporary equity to redemption value

 

(88,380)

 

(4,120)

Net income (loss) including accretion of temporary equity to redemption value

$

1,385,023

$

(116,407)

For the three months ended

June 30, 

2022

2021

    

Class A

    

Class B

    

Class A

    

Class B

Basic and diluted net income per share:

 

  

 

  

 

  

 

  

Numerator:

 

  

 

  

 

  

 

  

Allocation of net income (loss) including accretion of temporary equity

 

$

1,108,018

 

$

277,005

 

$

(93,126)

 

$

(23,281)

Accretion of temporary equity to redemption value

 

88,380

 

 

4,140

 

Allocation of net income (loss)

$

1,196,398

$

277,005

$

(88,986)

$

(23,281)

Denominator:

 

  

 

  

 

  

 

  

Weighted-average shares outstanding

 

13,800,000

 

3,450,000

 

13,800,000

 

3,450,000

Basic and diluted net income (loss) per share

$

0.09

$

0.08

$

(0.01)

$

(0.01)

11

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

For the

For the

six months ended

six months ended

    

June 30, 2022

    

June 30, 2021

Net income (loss)

$

5,046,742

$

(517,965)

Accretion of temporary equity to redemption value

 

(91,783)

 

(13,385,719)

Net income (loss) including accretion of temporary equity to redemption value

$

4,954,959

$

(13,903,684)

For the six months ended 

June 30,

2022

2021

    

Class A

    

Class B

    

Class A

    

Class B

Basic and diluted net income per share:

  

  

  

  

Numerator:

 

  

 

  

 

  

 

  

Allocation of net income (loss) including accretion of temporary equity

$

3,963,967

$

990,992

$

(11,122,947)

$

(2,780,737)

Accretion of temporary equity to redemption value

 

91,783

 

 

13,385,719

 

Allocation of net income (loss)

$

4,055,750

$

990,992

$

2,262,772

$

(2,780,737)

 

 

Denominator:

 

  

 

  

 

  

 

  

Weighted-average shares outstanding

 

13,800,000

 

3,450,000

 

9,149,171

 

3,298,343

Basic and diluted net income (loss) per share

$

0.29

$

0.29

$

0.25

$

(0.84)

In connection with the underwriters’ full exercise of the over-allotment option on March 2, 2021, 450,000 Founder Shares were no longer subject to forfeiture. These shares were excluded from the calculation of weighted average shares outstanding until they were no longer subject to forfeiture.

As of June 30, 2022 and 2021, there are no other dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in our earnings. As a result, diluted loss per share is the same as basic loss per share for the periods presented. The Founder Shares were not included to calculate earnings per share as including the Founder Shares would be anti-dilutive.

Income Taxes

ASC 740, Income Taxes, prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2022 and December 31, 2021. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

There is currently no taxation imposed on income by the government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed financial statements.

12

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

Risks and Uncertainties

Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, liquidity and/or search for a target company, the specific impact is not readily determinable as of the date of these unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Recent Accounting Standards

In August 2020, the FASB issued ASU 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company early adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company’s unaudited condensed financial statements.

NOTE 3. PUBLIC OFFERING

Pursuant to the Initial Public Offering, the Company sold 13,800,000 Units, which includes a full exercise by the underwriters of their over-allotment option in the amount of 1,800,000 Units, at a purchase price of $10.00 per Unit. Each Unit consists of one Class A ordinary share and one-half of one redeemable warrant (“Public Warrant”). Each whole Public Warrant entitles the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 9).

NOTE 4. PRIVATE PLACEMENT

Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 4,835,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $4,835,000 from the Company in a private placement. Each Private Placement Warrant is exercisable to purchase one Class A ordinary share at a price of $11.50 per share. The proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. The difference between the initial fair value of $0.80 per Private Placement Warrants (or $3,868,000) (see Note 9) and the purchase of $1.00 per Private Placement Warrants of $967,000 was recorded in additional paid-in capital.

NOTE 5. RELATED PARTY TRANSACTIONS

Founder Shares

On November 15, 2020, the Sponsor purchased 2,875,000 Class B ordinary shares (the “Founder Shares”) for an aggregate consideration of $25,000. On January 11, 2021, the Sponsor transferred an aggregate of 100,000 Founder Shares to four members of the Company’s board of directors (each received 25,000 Founder Shares). On February 25, 2021, the Company effected a share dividend of 575,000 Class B ordinary shares, resulting in there being an aggregate of 3,450,000 Founder Shares outstanding. As a result of the underwriters’ election to fully exercise their over-allotment option, no Founder Shares are currently subject to forfeiture.

13

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, sold or released from escrow until the earlier of (A) one year after the completion of a Business Combination or (B) subsequent to a Business Combination, (x) if the last reported sale price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share capitalizations reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property.

The sale or transfers of the Founders Shares to members of the Company’s board of directors, as described above, is within the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 100,000 shares granted to the Company’s board of directors was $401,000 or $4.01 per share. The Founders Shares were effectively sold or transferred subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. A business combination is not probable until it is completed. Stock-based compensation would be recognized at the date a Business Combination is considered probable in an amount equal to the number of Founders Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founders Shares. As of June 30, 2022, the Company determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized.

Related Party Units Purchased

Simultaneously with the closing of the Initial Public Offering, one of the Company’s directors purchased 10,000 Units sold at the Initial Public Offering at a price of $10.00 per Unit, for an aggregate purchase price of $100,000. If the Company seeks shareholder approval in connection with a Business Combination, the director has agreed to vote his Public Shares in favor of approving a Business Combination. The director has agreed to not redeem any shares of Class A ordinary shares in connection with shareholder approval of the Business Combination. There are no restrictions on the sale of any of the units purchased, and, therefore, the Class A ordinary shares is not contingent to this restriction. Accordingly, these Public Shares are recorded in Class A ordinary shares subject to possible redemption.

Administrative Services Agreement

The Company entered into an agreement, commencing on February 25, 2021, through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay the Sponsor a total of up to $10,000 per month for office space, utilities and secretarial and administrative support. For the three and six months ended June 30, 2022, the Company incurred and paid $30,000 and $60,000 in fees for these services, respectively. For the three and six months ended June 30, 2021, the Company incurred and paid $30,000 and $40,000 in fees for these services.

Promissory Note — Related Party

On November 15, 2020, the Company issued a promissory note (the “Promissory Note”) to the Sponsor, pursuant to which the Company could borrow up to an aggregate principal amount of $300,000. The Promissory Note was non-interest bearing and payable on the earlier of (i) June 30, 2021 or (i) the consummation of the Initial Public Offering. The Company borrowed $200,159 under the Promissory Note, and fully repaid the Promissory Note on April 16, 2021. On May 5, 2022, the Company issued a promissory note to the Sponsor, pursuant to which the Company borrowed an aggregate principal amount of $80,040 from the Sponsor (the “Simple Promissory Note”). The Simple Promissory Note is non-interest bearing and payable upon a Business Combination. On June 30, 2022, the Company issued an additional Simple Promissory Note to the Sponsor, pursuant to which the Company borrowed an aggregate principal amount of $79,626 from the Sponsor. As of June 30, 2022, the Company repaid $800 of the Simple Promissory Notes. As of June 30, 2022 and December 31, 2021, the Company had $158,866 outstanding borrowings under the Simple Promissory Note and $0 outstanding borrowings under the Promissory Note, respectively.

14

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

Related Party Loans

In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s directors and officers may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company will repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. As of June 30, 2022 and December 31, 2021, the Company has not entered into any related party loans.

NOTE 6. COMMITMENTS AND CONTINGENCIES

Registration and Shareholder Rights

Pursuant to a registration rights agreement entered into on February 25, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of the Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) have registration rights requiring the Company to register a sale of any of its securities held by them. The holders of these securities will be entitled to make up to three demands, excluding short form demands, that the Company register such securities under the Securities Act. In addition, the holders will have certain “piggy-back” registration rights to include their securities in other registration statements filed by the Company, subject to certain limitations. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $4,830,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. If the Business Combination does not occur, the fee is forfeited.

Contingent Fees

As of June 30, 2022, the Company incurred legal fees of approximately $668,000. These fees will only become due and payable upon the consummation of an initial Business Combination.

As of June 30, 2022, the Company incurred consulting fees of approximately $40,000. These fees will only become due and payable upon the consummation of an initial Business Combination.

NOTE 7. SHAREHOLDERS’ DEFICIT

Preference Shares The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. At June 30, 2022 and December 31, 2021, there were no preferred shares issued or outstanding.

15

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

Class A Ordinary Shares The Company is authorized to issue 300,000,000 Class A ordinary shares, with a par value of $0.0001 per share. Holders of Class A ordinary shares are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were 13,800,000 Class A ordinary shares issued and outstanding, including Class A ordinary shares subject to possible redemption which are presented as temporary equity.

Class B Ordinary Shares The Company is authorized to issue 30,000,000 Class B ordinary shares, with a par value of $0.0001 per share. Holders of the Class B ordinary shares are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were 3,450,000 Class B ordinary shares issued and outstanding.

Prior to a Business Combination, only holders of the Founder Shares will have the right to vote on the appointment of directors. Holders of the Public Shares will not be entitled to vote on the appointment of directors during such time. In addition, prior to the completion of a Business Combination, holders of a majority of the Founder Shares may remove a member of the board of directors for any reason. Holders of Class A ordinary shares and Class B ordinary shares will vote together as a single class on all matters submitted to a vote of shareholders.

The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional Class A ordinary shares or equity-linked securities are issued or deemed issued in connection with a Business Combination, the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all ordinary shares outstanding upon the completion of the Initial Public Offering, plus the total number of Class A ordinary shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in a Business Combination and any private placement-equivalent warrants issued to the Sponsor, officers or directors upon conversion of Working Capital Loans, except that such conversion of Founder Shares will never occur on a less than one for one basis.

NOTE 8. WARRANTS

Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years from the completion of a Business Combination or earlier upon redemption or liquidation.

The Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating thereto is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption is available.

16

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the issuance, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its best efforts to file with the SEC a registration statement registering the issuance of the Class A ordinary shares issuable upon exercise of the warrants, to cause such registration statement to become effective and to maintain a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th business day after the closing of a Business Combination or within a specified period following the consummation of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” pursuant to the exemption provided by Section 3(a)(9) of the Securities Act; provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.

Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants:

in whole and not in part;
at a price of $0.01 per warrant;
upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and
if, and only if, the reported closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to the warrant holders.

If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

The exercise price and number of ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless.

In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

17

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

NOTE 9. FAIR VALUE MEASUREMENTS

At June 30, 2022 and December 31, 2021, assets held in the Trust Account were comprised of $138,108,723 and $138,016,940 in money market funds which are invested primarily in U.S. Treasury Securities.

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

Description

    

Level

    

June 30, 2022

    

December 31, 2021

Assets:

 

  

 

  

Marketable securities held in Trust Account

 

1

$

138,108,723

$

138,016,940

Liabilities:

 

  

 

Warrant Liability – Public Warrants

1

552,000

3,726,000

Warrant Liability – Private Placement Warrants

 

2

386,800

2,610,900

The Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the accompanying unaudited condensed balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the unaudited condensed statements of operations.

Initial Measurement

The Company established the initial fair value for the Warrants on March 2, 2021, the date of the Company’s Initial Public Offering, using a Monte-Carlo simulation model for the Private Placement Warrants and the Public Warrants. The Public Warrants and Private Placement Warrants were initially recorded at a fair value of $5,382,000 and $3,868,000, respectively. The Warrants were classified as Level 3 at the initial measurement date due to the use of unobservable inputs.

The key inputs into the Monte-Carlo simulation model for the Private Placement Warrants were as follows at initial measurement:

    

March 2, 2021

 

(Initial

 

Input

Measurement)

 

Risk-free interest rate

 

0.82

%

Term in years

 

5.8

Expected volatility

 

14.0

%

Exercise price

$

11.50

Stock Price

$

9.60

On March 2, 2021, the Private Placement Warrants and Public Warrants were determined to be $0.80 and $0.78 per warrant for aggregate values of $3.87 million and $5.38 million, respectively.

18

Table of Contents

IBERE PHARMACEUTICALS

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2022

(Unaudited)

Subsequent Measurement

The Warrants are measured at fair value on a recurring basis.

For periods subsequent to the detachment of the Public Warrants from the Units, which occurred on April 20, 2021, the Public Warrants were valued using the instrument’s publicly listed trading price on the New York Stock Exchange as of the balance sheet date, which is considered to be a Level 1 measurement due to the use of an observable market quote in an active market.

For periods subsequent to the detachment of the Public Warrants from the Units, the Private Placement Warrants were valued using the Public Warrant trading price, which is considered to be a Level 2 measurement due to the use of an observable market quote for a similar asset in an active market.

As of December 31, 2021, the aggregate values of the Private Placement Warrants and Public Warrants were $2.6 million and $3.7 million, respectively.

The following table presents the changes in the fair value of the Level 3 warrant liabilities:

   

Private Placement

   

Public

   

Warrant Liabilities

Fair value as of December 31, 2020

$

$

$

Initial measurement on March 2, 2021 (IPO) as restated

 

3,868,000

5,382,000

9,250,000

Change in valuation inputs or other assumptions

(1,257,100)

(1,656,000)

(2,913,100)

Transfer to Level 1

(3,726,000)

(3,726,000)

Transfer to Level 2

(2,610,900)

(2,610,900)

Fair value as of December 31, 2021

$

$

$

Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. The estimated fair value of the Private Placement Warrants transferred from a Level 3 measurement to a Level 2 measurement when the Public Warrants were separately listed and traded. The transfers out of Level 3 of the fair value hierarchy into Level 2 totaled $2,610,900 for the year ended December 31, 2021. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 measurement when the Public Warrants were separately listed and traded. The transfers out of Level 3 of the fair value hierarchy into Level 1 totaled $3,726,000 for the year ended December 31, 2021.

19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References in this report (this “Quarterly Report”) to “we,” “us” or the “Company” refer to Ibere Pharmaceuticals. References to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to PIPV Capital LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s final prospectus for its Initial Public Offering filed with the SEC. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

We are a blank check company incorporated in the Cayman Islands on October 22, 2020 formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar Business Combination with one or more businesses. We intend to effectuate our Business Combination using cash derived from the proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, our shares, debt or a combination of cash, shares and debt.

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful.

Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities from October 22, 2020 (inception) through June 30, 2022 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on marketable securities held in the Trust Account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

For the three months ended June 30, 2022, we had a net income of $1,473,403, which consists of interest earned on marketable securities held in the Trust Account of $88,380 and change in fair value of warrants $1,525,550, offset by formation and operating costs of $140,527.

For the six months ended June 30, 2022, we had a net income of $5,046,742, which consists of interest earned on marketable securities held in the Trust Account of $91,783 and change in fair value of warrants $5,398,100, offset by formation and operating costs of $443,141.

20

For the three months ended June 30, 2021, we had a net loss of $112,267, which consists of formation and operating costs of $233,757 and unrealized loss on marketable securities held in the Trust Account of $1,989, offset by interest earned on marketable securities held in the Trust Account of $6,129 and change in fair value of warrants $117,350.

For the six months ended June 30, 2021, we had a net loss of $517,965, which consists of formation and operating costs of $328,235 and transaction costs related to warrant liabilities of $364,321, offset by interest earned on marketable securities held in the Trust Account of $8,715, change in fair value of warrants $165,700 and interest income from the bank of $176.

Liquidity and Capital Resources

On March 2, 2021, we completed the Initial Public Offering of 13,800,000 Units, at $10.00 per Unit, generating gross proceeds of $138,000,000. Simultaneously with the closing of our Initial Public Offering, we completed the sale of 4,835,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor, generating gross proceeds of $4,835,000.

Following our Initial Public Offering, the full exercise of the over-allotment option, and the sale of the Private Placement Warrants, a total of $138,000,000 was placed in the Trust Account. We incurred $8,359,325 in Initial Public Offering related costs, including $2,760,000 of underwriting fees, $4,830,000 of deferred underwriting fees and $769,325 of other offering costs.

For the six months ended June 30, 2022, net cash used in operating activities was $524,213. The net income of $5,046,742 was affected by noncash charges related to the change in fair value of the warrant liability of $5,398,100 and interest earned on marketable securities held in the Trust Account of $91,783. Changes in operating assets and liabilities used $81,072 of cash from operating activities.

For the six months ended June 30, 2021, net cash used in operating activities was $623,233. The net loss of $517,965 was affected by noncash charges related to the change in fair value of the warrant liability of $165,700, transaction costs incurred in connection with warrant liability of $364,321 and interest earned on marketable securities held in Trust Account of $8,715. Changes in operating assets and liabilities used $295,174 of cash from operating activities.

As of June 30, 2022, we had marketable securities held in the Trust Account of $138,108,723 (including approximately $108,723 of interest income and unrealized gains) consisting of U.S. government securities with a maturity of 185 days or less. We may withdraw interest from the Trust Account to pay taxes, if any. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less income taxes payable), to complete our Business Combination. To the extent that our share capital or debt is used, in whole or in part, as consideration to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

As of June 30, 2022, we had cash of $93,041. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete a Business Combination.

21

In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor, or certain of our officers and directors or their affiliates may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we will repay such loaned amounts. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants.

If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.

As a result of the above, in connection with the Company’s assessment of going concern considerations in accordance with FASB’s ASC Subtopic 205-40, “Presentation of Financial Statements – Going Concern,” management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company’s ability to continue as a going concern through approximately one year from the date of filing of this report. These unaudited condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Contractual obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations, off-balance sheet arrangements or long-term liabilities, other than an agreement to the Sponsor a monthly fee of $10,000 for office space, utilities, and secretarial and administrative support. We began incurring these fees on February 25, 2021 and will continue to incur these fees monthly until the earlier of the completion of the Business Combination and our liquidation.

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $4,830,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

Critical Accounting Policies and Estimates

The preparation of condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates.

See Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021 for identified critical accounting policies and a more detailed discussion of our significant accounting policies and critical accounting estimates.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for smaller reporting companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

22

Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2022, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation and in light of the material weakness in internal controls described below, our principal executive officer and principal financial and accounting officer have concluded that during the period covered by this report, our disclosure controls and procedures were not effective. Due to this error’s impact on our financial statements, we determined this to be a material weakness. This error in classification was brought to our attention only when the SEC issued a Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies dated April 12, 2021. Upon further evaluation, as further described in our amended March 31, 2021 Quarterly Report due to the events that led to the restatement, a material weakness in our internal controls also exists as it relates to the accounting for temporary and permanent equity.

As a result, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. generally accepted accounting principles. Accordingly, management believes that the unaudited condensed financial statements included in this Form 10-Q present fairly in all material respects our financial position, results of operations, and cash flows for the period presented.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period ended June 30, 2022 covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, other than as described herein. Management has implemented remediation steps to address the material weakness and to improve our internal control over financial reporting. Specifically, we enhanced the supervisory review of accounting procedures in this financial reporting area and expanded and improved our review process for complex securities and related accounting standards. As of June 30, 2022, this had not been fully remediated. We can offer no assurance that we will be able to fully remediate the material weakness.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

None

Item 1A. Risk Factors

Factors that could cause our actual results to differ materially from those in this report include the risks described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 10-K”). Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in the 2021 10-K, except for the below risk factor. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial business combination, and results of operations.

We are subject to laws and regulations enacted by national, regional and local governments. In particular, we will be required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Laws and regulations and their interpretation and application may also change from time to time and such changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business, including our ability to negotiate and complete our initial business combination, and results of operations.

23

On March 30, 2022, the SEC issued proposed rules that would, among other things, impose additional disclosure requirements for initial public offerings by special purpose acquisition companies (“SPACs”)  and business combination transactions involving SPACs and private operating companies; amend the financial statement requirements applicable to business combination transactions involving such companies; update and expand guidance regarding the general use of projections in SEC filings, as well as when projections are disclosed in connection with proposed business combination transactions; increase the potential liability of certain participants in proposed business combination transactions; and impact the extent to which SPACs could become subject to regulation under the Investment Company Act of 1940. These rules, if adopted, whether in the form proposed or in revised form, may materially adversely affect our business, including our ability to negotiate and complete our initial business combination and may increase the costs and time related thereto.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On March 2, 2021, we consummated the Initial Public Offering of 13,800,000 Units. The Units were sold at an offering price of $10.00 per Unit, generating total gross proceeds of $138,000,000. Raymond James & Associates, Inc. acted as sole book-running manager of the Initial Public Offering. The securities in the offering were registered under the Securities Act on registration statement on Form S-1 (Nos. 333-252863 and 333-253552). The SEC declared the registration statements effective on February 25, 2021.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 4,835,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor, generating gross proceeds of $4,835,000. Each whole Private Placement Warrant is exercisable to purchase one Class A ordinary share at an exercise price of $11.50 per share. The issuance was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

The Private Placement Warrants are identical to the warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants are not transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions.

Of the gross proceeds received from the Initial Public Offering, the exercise of the over-allotment option and the Private Placement Warrants, an aggregate of $138,000,000 was placed in the Trust Account.

We paid a total of $2,760,000 of underwriting fees and $769,325 for other costs and expenses related to the Initial Public Offering.

For a description of the use of the proceeds generated in our Initial Public Offering, see Part I, Item 2 of this Form 10- Q.

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

None

24

Item 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

No.

    

Description of Exhibit

31.1*

Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*

Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*

XBRL Instance Document

101.SCH*

XBRL Taxonomy Extension Schema Document

101.CAL*

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*

XBRL Taxonomy Extension Labels Linkbase Document

101.PRE*

XBRL Taxonomy Extension Presentation Linkbase Document

104*

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*Filed herewith.

25

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IBERE PHARMACEUTICALS

Date: August 12, 2022

By:

/s/ Osagie Imasogie

Name:

Osagie Imasogie

Title:

Chief Executive Officer and Director

(Principal Executive Officer)

Date: August 12, 2022

By:

/s/ Lisa Gray

Name: